logo

Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies for common gynecological conditions that improve and save lives.

Gynion is developing ablative gels for multiple indications in Women’s Health addressing unmet needs in several markets with a combined value of $69 Billion. Our therapeutic platform presents an opportunity to commercialize several products with an immediate focus on Clarablex for the treatment of cervical intraepithelial neoplasia (CIN) to prevent cervical cancer and Menorrx therapy for Heavy Menstrual Bleeding (HMB) to alleviate iron-deficiency anemia. Our future product Senoblex will offer an early treatment and prevention of breast cancer.

ClarablexTM is an ablative topical gel for multiple indications in gynecology, including the treatment of cervical intraepithelial neoplasia (CIN) to prevent cervical cancer and other diseases caused by human papillomavirus (HPV). A need for capital equipment, the cost of its maintenance, repairs, and training, and a growing global shortage of skilled providers, including in the US, limit access to therapy resulting in delays or no treatment at all for millions of women. Clarablex is a simple, non-invasive treatment that requires no capital equipment and is ready for immediate use not just by doctors, but also by nurse practitioners, and other healthcare providers trained in cervical cancer screening as soon as the woman is diagnosed with CIN. Clarablex’s affordability will enable all screening centers, even those in low- and middle-income countries, to stock it, removing any obstacles to healthcare access and allowing more women to receive timely treatment to prevent cervical cancer.

MenorrxTM is a therapy for Heavy Menstrual Bleeding (HMB). Menorrx stops or significantly reduces bleeding and alleviates iron-deficiency anemia. It is simpler, easier to use, and costs much less than other endometrial ablation alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to disrupt this market and change the way women are treated for HMB both in developed markets and low-resource countries.

SenoblexTM will ablate ductal areas affected by atypical hyperplasia, Intraductal Papilloma, Ductal Carcinoma in Situ, and surgical sites after Lumpectomy.

Management Team

Oleg Shikhman

Founder & CEO

Victoria Shikhman, ND

Founder & VP of Clinical Research
Doctor of Naturopathic Medicine

Steven Goldstein, MD

Co-founder & Chief Medical Officer
Professor of OBGYN at NYU Medical Center

Nicole Shugrue

Marketing Advisor

Julie Gionfriddo

Business Development Advisor

Dana Dunn

Regulatory Advisor

Clinical Advisors

Malcolm Munro, MD

Professor of OBGYN, UCLA
FIGO Menstrual Disorders Committee

Amy Garcia, MD

Medical Director, The Center for Women’s Surgery

Paul Blumenthal, MD

Professor of OBGYN,
Stanford University

Tulay Okman Kilic, MD

Professor of OBGYN
Istambul, Turkey

Juan Canela Oleaga, MD

Director of OBGYN Surgery
Dominical Republic

Contact Us

Oleg Shikhman, CEO
Gynion LLC
oshikhman@bridgeinnovations.com